These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
675 related articles for article (PubMed ID: 32283499)
1. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Singh AK; Gupta R; Misra A Diabetes Metab Syndr; 2020; 14(4):283-287. PubMed ID: 32283499 [TBL] [Abstract][Full Text] [Related]
2. Delineating clinical characteristics and comorbidities among 206 COVID-19 deceased patients in India: Emerging significance of renin angiotensin system derangement. Majeed J; Ajmera P; Goyal RK Diabetes Res Clin Pract; 2020 Sep; 167():108349. PubMed ID: 32712124 [TBL] [Abstract][Full Text] [Related]
3. Compliance of Antihypertensive Medication and Risk of Coronavirus Disease 2019: a Cohort Study Using Big Data from the Korean National Health Insurance Service. Kim J; Kim DW; Kim KI; Kim HB; Kim JH; Lee YG; Byeon KH; Cheong HK; J Korean Med Sci; 2020 Jun; 35(25):e232. PubMed ID: 32597045 [TBL] [Abstract][Full Text] [Related]
4. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? Patel AB; Verma A JAMA; 2020 May; 323(18):1769-1770. PubMed ID: 32208485 [No Abstract] [Full Text] [Related]
5. [Association of hypertension and antihypertensive agents and the severity of COVID-19 pneumonia. A monocentric French prospective study]. Georges JL; Cochet H; Roger G; Ben Jemaa H; Soltani J; Azowa JB; Mamou R; Gilles F; Saba J; Prevot A; Pasqualini M; Monguillon V; De Tournemire M; Bertrand A; Koukabi-Fradelizi M; Beressi JP; Livarek B Ann Cardiol Angeiol (Paris); 2020 Nov; 69(5):247-254. PubMed ID: 33039120 [TBL] [Abstract][Full Text] [Related]
6. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19. Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367 [TBL] [Abstract][Full Text] [Related]
7. Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection. Salah HM; Calcaterra G; Mehta JL J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):503-507. PubMed ID: 32748634 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular disease and the impact of COVID-19. Yoganathan A; Sajjad MS; Harky A J Card Surg; 2020 Aug; 35(8):2113. PubMed ID: 32542799 [No Abstract] [Full Text] [Related]
9. Drugs and the renin-angiotensin system in covid-19. Aronson JK; Ferner RE BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880 [No Abstract] [Full Text] [Related]
10. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202 [TBL] [Abstract][Full Text] [Related]
11. The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases. Askin L; Tanrıverdi O; Askin HS Arq Bras Cardiol; 2020 Jun; 114(5):817-822. PubMed ID: 32491073 [TBL] [Abstract][Full Text] [Related]
12. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension? Huang Y; Xie C; Chen X; Hong Q; Huang H Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834 [No Abstract] [Full Text] [Related]
13. COVID-19: The heart of the issue. Woodward B; Kermali M J Card Surg; 2020 Aug; 35(8):2112. PubMed ID: 32542802 [No Abstract] [Full Text] [Related]
14. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Danser AHJ; Epstein M; Batlle D Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019. Sanchis-Gomar F; Lavie CJ; Perez-Quilis C; Henry BM; Lippi G Mayo Clin Proc; 2020 Jun; 95(6):1222-1230. PubMed ID: 32376099 [TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors. Zhou X; Zhu J; Xu T Clin Exp Hypertens; 2020 Oct; 42(7):656-660. PubMed ID: 32404011 [TBL] [Abstract][Full Text] [Related]
17. A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far? Kurdi A; Abutheraa N; Akil L; Godman B Pharmacol Res Perspect; 2020 Dec; 8(6):e00666. PubMed ID: 33084232 [TBL] [Abstract][Full Text] [Related]
18. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Pranata R; Permana H; Huang I; Lim MA; Soetedjo NNM; Supriyadi R; Soeroto AY; Alkatiri AA; Firman D; Lukito AA Diabetes Metab Syndr; 2020; 14(5):983-990. PubMed ID: 32615377 [TBL] [Abstract][Full Text] [Related]
19. [The RAAS and SARS-CoV-2: A riddle to solve]. Choi M; Aiello EA; Ennis IL; Villa-Abrille MC Hipertens Riesgo Vasc; 2020; 37(4):169-175. PubMed ID: 32527699 [TBL] [Abstract][Full Text] [Related]
20. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study. Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]